The recent profile of Medvi by The New York Times earlier this month highlighted the company as a prime example…
Read More
Lilly’s plans to buy CAR-T firm Kelonia in deal worth up to $7 billion. Can its deal spree avoid Pfizer’s fate?
Eli Lilly and Company, currently buoyed by the explosive success of its GLP-1 franchise, has announced its intent to acquire…
Read More
Chinese firms landed 6 of 26 major pharma deals in 16 months, worth $53 billion
The majority of these high-value collaborations, roughly half, involved firms of U.S. origin, predominantly structured as mergers and acquisitions (M&A).…
Read More
Isomorphic Labs Secures $2.1 Billion in Series B Funding to Accelerate AI-Driven Drug Discovery and Development
AI drug design and development firm Isomorphic Labs has successfully closed a significant $2.1 billion Series B funding round, marking…
Read More
Bristol Myers Squibb and Hengrui Pharma Forge Landmark $15.2 Billion Oncology and Immunology Collaboration
Bristol Myers Squibb (BMS) and Chinese biopharmaceutical giant Hengrui Pharma have announced a monumental licensing and collaboration agreement, potentially valued…
Read More
Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1 Billion to Bolster Rare Disease and Brain Health Portfolio
Angelini Pharma, a prominent player in the pharmaceutical sector, has announced a definitive agreement to acquire Catalyst Pharmaceuticals for an…
Read More
Medvi: The $1.8 Billion Telehealth Company Built on Regulatory Gaps, Fake Testimonials, and AI Deception
A recent profile by The New York Times lauded Medvi as a prime example of artificial intelligence’s potential to empower…
Read More
Insilico CEO Sees Potentially $2.75 Billion Collaboration as ‘Fusing Lilly’s Clinical Excellence’ with Insilico’s ‘End-to-End AI Engine’
On March 29, Insilico Medicine, a pioneer in artificial intelligence (AI)-driven drug discovery and development, announced a landmark collaboration with…
Read More
Eli Lilly Pledges $4.5 Billion to Expand Indiana Manufacturing, Bolstering US Pharmaceutical Supply Chain
Eli Lilly and Company is significantly expanding its manufacturing footprint in Indiana with a substantial $4.5 billion investment, pushing its…
Read More
Lilly’s plans to buy CAR-T firm Kelonia in deal worth up to $7 billion. Can its deal spree avoid Pfizer’s fate?
Eli Lilly and Company, a pharmaceutical giant currently experiencing unprecedented growth driven by its blockbuster GLP-1 agonists, has announced its…
Read More
